Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0909 BTS45 de Rubertis Podcast
BioCentury & Getty Images

Back to School 2020

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

de Rubertis believes COVID-19 could be the trigger to push for legislative action on infectious disease incentives

VC Francesco de Rubertis believes COVID-19 could be the trigger to push for legislative action on infectious disease incentives.

Sep 10, 2020 | 2:10 AM GMT

Francesco de Rubertis, co-founder and partner of Medicxi, is optimistic that the COVID-19 pandemic might lead to an increased interest in infectious disease investment, but it will take government action to create the incentives.

de Rubertis spoke to BioCentury on an audio interview as part of the Back to School 2020 series (see Cover Story: “Back to School 2020”). 

de Rubertis thinks the pandemic could be a turning point for infectious disease, an area that has had little investment due to the lack of market incentives. Antimicrobial resistance (AMR) has been a particularly difficult area, with many pharmas having withdrawn, and some small companies going out of business even after gaining approval for their products.

“I’m sure that this COVID situation will represent a paradigm for all the infectious disease crises that we have just

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE